Close Menu

NEW YORK (GenomeWeb) – Definiens announced today that Takeda Pharmaceuticals will use its new cloud-based digital pathology platform in its translational and biomarker research.

When combined with deeply researched biomarker analysis, Definiens said its new platform, VeriTrova, can help translate biomarker research into the clinic through a new generation of diagnostics. Takeda, an early adopter of the platform, plans to use it for comprehensive tissue-based analysis in its clinical trials, and to support its clinical biomarker development programs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.